pertuzumab,pembrolizumab,dostarlimab,talazoparib,durvalumab,trastuzumab,olaparib,paclitaxel,neratinib,cemiplimab,ganetespib,irinotecan,tucatinib
gsk,bms,amgen,astrazeneca,daiichi sankyo,merck,roche
['i-spy', 'breast']
i-spy2 trial results presented at #asco22 show molecular subtypes within hr+/her2-negative #breastcancer may help predict which patients respond better to therapies &amp; personalize medicine 
A force united by a promise to end breast cancer, funding groundbreaking research, community health & advocacy programs globally.
https://t.co/dvoS7vv1mZ